Feature

Twenty percent of dialysis patients are hesitant about COVID-19 vaccine


 

Possible adverse effects an issue

Asked the reason why they were hesitant to receive the vaccine, 53% cited possible adverse effects; 19% cited general unease about vaccines; 19% said they did not think the COVID-19 vaccines would work; 17% said they did not think they needed a COVID-19 vaccine; and 15% said they had read or heard that COVID-19 vaccines were dangerous.

A set of questions asked survey respondents about their primary source of information about COVID-19 vaccines. About three-quarters cited television news; about 35% cited members of their dialysis clinic staff; about 30% cited friends and family; 20% cited social media; 20% cited their nephrologists; and roughly 15% cited newspapers.

The results suggest that potentially effective interventions to promote vaccine uptake include showing informational videos to patients during dialysis sessions and encouraging the staff at dialysis centers to proactively educate patients about COVID-19 vaccines and to promote uptake, suggest Dr. Garcia and Dr. Vassalotti.

Dr. Vassalotti noted that in a recent single-center survey of 90 U.S. patients undergoing hemodialysis that included 75 (85%) Black persons, the prevalence of hesitancy about COVID-19 vaccines was 50%. Hesitancy was often linked with gaps in patient education.

“We need broad educational measures, as well as targeting specific demographic groups” among whom the level of hesitancy is high, said Dr. Vassalotti.

He noted that patients who undergo dialysis are receptive to messages from dialysis clinic staff members and that this offers an “opportunity to understand misconceptions that underlie hesitancy and address them on an individual basis.”

The NKF has prepared a fact sheet for educating patients with kidney disease about the efficacy and safety of COVID-19 vaccines, Dr. Vassalotti noted.

Dr. Garcia has disclosed no relevant financial relationships. Dr. Vassalotti is an adviser and consultant to Renalytix AI and is a consultant to Janssen.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Researchers stress importance of second COVID-19 vaccine dose for infliximab users
MDedge Rheumatology
About one in five clinicians considers quitting because of pandemic
MDedge Rheumatology
‘Beyond a reasonable doubt’: COVID-19 brain health fallout is real, severe
MDedge Rheumatology
U.S. finally hits its stride with COVID-19 vaccination rollouts
MDedge Rheumatology
FDA, CDC urge pause of J&J COVID vaccine
MDedge Rheumatology
Next winter may be rough: Models predict ‘considerable surge’ of COVID
MDedge Rheumatology
Data about COVID-19-related skin manifestations in children continue to emerge
MDedge Rheumatology
How to counsel worried patients about the J&J vaccine news
MDedge Rheumatology
How some COVID-19 vaccines could cause rare blood clots
MDedge Rheumatology
CDC panel: Pause of J&J COVID-19 vaccine to remain for now
MDedge Rheumatology